Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the LDL-C lowering efficacy of ER niacin/laropiprant (1 to 2g) compared with placebo in patients with Type 2 diabetes.
Critère d'inclusion
- type II diabetes mellitus
To evaluate the LDL-C lowering efficacy of ER niacin/laropiprant (1 to 2g) compared with placebo in patients with Type 2 diabetes.